[Question] shortage list — what am I missing here
Question in the title, detail here: shortage list — what am I missing here.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
the label on a compounded vial is a legal document, read it
potency testing on the finished preparation is the thing to ask for
salt forms are the recurring argument and the answer is boring
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
ask which facility, then ask for their testing
What is the beyond-use date and what is it based on?
What concentration is on the label, and does it match what you were expecting?
What did the intake actually ask you?
[deleted]
shortage status changes and the whole arrangement changes with it